Document:

Document

Exhibit 10.1

AMENDMENT NO. 2 TO WARRANT AGREEMENT
This Amendment (this “Amendment”) is made as of August 23, 2022 by and between Perella Weinberg Partners, a Delaware corporation (the “Company”) (f/k/a FinTech Acquisition Corp. IV (“FTIV”)), and American Stock Transfer & Trust Company, LLC, as warrant agent (the “Warrant Agent”), and constitutes an amendment to that certain Warrant Agreement, dated as of September 24, 2020, by and between the Company and Continental Stock Transfer & Trust Company, as amended by Amendment No. 1 to Warrant Agreement, dated as of November 10, 2021, by and among the Company, Continental Stock Transfer & Trust Company and the Warrant Agent (the “Existing Warrant Agreement”). Capitalized terms used but not otherwise defined in this Amendment shall have the meanings given to such terms in the Existing Warrant Agreement.
WHEREAS, on June 24, 2021, the Company consummated the business combination pursuant to that certain Business Combination Agreement, dated as of December 29, 2020, by and among FTIV, FinTech Investor Holdings IV, LLC, a Delaware limited liability company, FinTech Masala Advisors, LLC, a Delaware limited liability company, PWP Holdings LP, a Delaware limited partnership, PWP GP LLC, a Delaware limited liability company and the general partner of PWP OpCo, PWP Professional Partners LP, a Delaware limited partnership and a limited partner of PWP OpCo, and Perella Weinberg Partners LLC, a Delaware limited liability company and the general partner of Professional Partners (the “Business Combination”), and in connection therewith the Company was renamed “Perella Weinberg Partners”;
WHEREAS, in accordance with Section 4.4 of the Existing Warrant Agreement, upon effectiveness of the Business Combination, the holders of the Warrants thereafter had the right to purchase and receive, upon the basis and upon the terms and conditions specified in the Warrants and in lieu of the shares of the Class A common stock of FTIV immediately theretofore purchasable and receivable upon the exercise of the rights represented thereby, an Alternative Issuance in shares of Class A common stock, par value $0.0001, per share, of the Company (the “Common Stock”);
WHEREAS, Section 9.8 of the Existing Warrant Agreement provides that the Company and the Warrant Agent may amend, subject to certain conditions provided therein, the Existing Warrant Agreement with the vote or written consent of the Registered Holders of 65% of the then outstanding Public Warrants;
WHEREAS, the Company desires to amend the Existing Warrant Agreement to provide the Company with the right to require the holders of the Warrants to exchange all of the outstanding Warrants for shares of Common Stock, on the terms and subject to the conditions set forth herein; and
WHEREAS, in the exchange offer and consent solicitation undertaken by the Company pursuant to the Registration Statement on Form S-4 filed with the U.S. Securities and Exchange Commission, the Registered Holders of more than 65% of the then outstanding Public Warrants consented to and approved this Amendment.
NOW, THEREFORE, in consideration of the mutual agreements contained herein and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, and intending to be legally bound hereby, the parties hereto agree to amend the Existing Warrant Agreement as set forth herein.
1.      Amendment of Existing Warrant Agreement. The Existing Warrant Agreement is hereby amended by adding:
(a)    the new Section 6A thereto:
“6A Mandatory Exchange.
6A.1 Company Election to Exchange. Notwithstanding any other provision in this Agreement to the contrary, all (and not less than all) of the outstanding Warrants (including outstanding Placement Warrants) may be exchanged, at the option of the Company, at any time while they are exercisable and prior to their expiration, at the office of the Warrant Agent, upon notice to the Registered Holders of the then outstanding Warrants, as described in Section 
1

6A.2 below, for Common Stock (or any Alternative Issuance pursuant to Section 4.4), at the exchange rate of 0.18 shares of Common Stock (or any Alternative Issuance pursuant to Section 4.4) for each Warrant held by the holder thereof (the “Consideration”) (subject to equitable adjustment by the Company in the event of any stock splits, stock dividends, recapitalizations or similar transaction with respect to the Common Stock). In lieu of issuing fractional shares, any holder of Warrants who would otherwise have been entitled to receive fractional shares as Consideration will, after aggregating all such fractional shares of such holder, be paid in cash (without interest) in an amount equal to such fractional part of a share multiplied by $7.85.
6A.2 Date Fixed for, and Notice of, Exchange. In the event that the Company elects to exchange all of the Warrants, the Company shall fix a date for the exchange (the “Exchange Date”). Notice of exchange shall be mailed by first class mail, postage prepaid, by the Company not less than fifteen (15) days prior to the Exchange Date to the Registered Holders at their last addresses as they shall appear on the registration books. Any notice mailed in the manner herein provided shall be conclusively presumed to have been duly given whether or not the registered holder received such notice. The Company will make a public announcement of its election following the mailing of such notice.
6A.3 Exercise After Notice of Exchange. The Warrants may be exercised, for cash (or on a “cashless basis” in accordance with subsection 3.3.1(b) of this Agreement, with an adjustment to the definition of “Fair Market Value” to substitute the date on which the notice of exchange is sent for the date on which the nature of redemption is sent) at any time after notice of exchange shall have been given by the Company pursuant to Section 6A.2 hereof and prior to the Exchange Date. On and after the Exchange Date, the Registered Holder of the Warrants shall have no further rights except to receive, upon surrender of the Warrants, the Consideration.
2.    Miscellaneous Provisions.
2.1    Severability. This Amendment shall be deemed severable, and the invalidity or unenforceability of any term or provision hereof shall not affect the validity or enforceability of this Amendment or of any other term or provision hereof. Furthermore, in lieu of any such invalid or unenforceable term or provision, the parties hereto intend that there shall be added as a part of this Amendment a provision as similar in terms to such invalid or unenforceable provision as may be possible and be valid and enforceable.
2.2    Applicable Law. The validity, interpretation, and performance of this Amendment and of the Warrants shall be governed in all respects by the laws of the State of New York, without giving effect to conflicts of law principles that would result in the application of the substantive laws of another jurisdiction. Each of the parties hereto hereby agrees that any action, proceeding or claim against it arising out of or relating in any way to this Amendment shall be brought and enforced in the courts of the State of New York or the United States District Court for the Southern District of New York, and irrevocably submits to such jurisdiction, which jurisdiction shall be exclusive. Each of the parties hereto hereby waives any objection to such exclusive jurisdiction and that such courts represent an inconvenient forum.
2.3    Counterparts. This Amendment may be executed in any number of counterparts (which may include counterparts delivered by any standard form of telecommunication) and each of such counterparts shall for all purposes be deemed to be an original, and all such counterparts shall together constitute but one and the same instrument. The words “execution,” “signed,” “signature,” and words of like import in this Amendment or in any other certificate, agreement or document related to this Amendment, if any, shall include images of manually executed signatures transmitted by facsimile or other electronic format (including, without limitation, “pdf,” “tif” or “jpg”) and other electronic signatures (including, without limitation, DocuSign and AdobeSign). The use of electronic signatures and electronic records (including, without limitation, any contract or other record created, generated, sent, communicated, received, or stored by electronic means) shall be of the same legal effect, validity and enforceability as a manually executed signature or use of a paper-based record-keeping system to the fullest extent permitted by applicable law, including the Federal Electronic Signatures in Global and National Commerce Act, the New York State Electronic Signatures and Records Act and any other applicable law, including, without limitation, any state law based on the Uniform Electronic Transactions Act or the Uniform Commercial Code.
2

2.4    Effect of Headings. The section headings herein are for convenience only and are not part of this Amendment and shall not affect the interpretation thereof.
2.5    Entire Agreement. The Existing Warrant Agreement, as modified by this Amendment, constitutes the entire understanding of the parties and supersedes all prior agreements, understandings, arrangements, promises and commitments, whether written or oral, express or implied, relating to the subject matter hereof, and all such prior agreements, understandings, arrangements, promises and commitments are hereby canceled and terminated.
[Signature Pages Follow]

3

IN WITNESS WHEREOF, each of the parties has caused this Amendment to be duly executed as of the date first above written.
						
	PERELLA WEINBERG PARTNERS

	 
	By:	 /s/ Gary Barancik
	 	Name:        Gary Barancik
	 	Title:          Chief Financial Officer
	 
	AMERICAN STOCK TRANSFER & TRUST COMPANY, LLC, as Warrant Agent

	 
	By:	/s/ Michael Legregin
	 	Name:      Michael Legregin
	 	Title:        Senior Vice President, Corporate Actions Relationship Management & Operations

4Exhibit 10.1

 

AMENDMENT TO EMPLOYMENT AGREEMENT

 

This Amendment (this “Amendment”)
effective as of the 22nd day of August, 2022 to the Employment Agreement, entered into as of December 7, 2021(the “Employment
Agreement”), by and between Adial Pharmaceuticals, Inc. (the “Company”) and Cary J. Claiborne (the “Executive”).
Capitalized terms used herein without definition shall have the meanings assigned in the Employment Agreement.  

 

WHEREAS, Executive was
retained under the Employment Agreement by the Corporation to serve as its Chief Operating Officer; and

 

WHEREAS, in recognition
of the hard work and performance by Executive, the Corporation desires to amend the Employment Agreement to, among other things, retain
Executive to serve as its Chief Executive Officer.

 

NOW THEREFORE, for the
mutual promises contained herein and for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged,
the parties hereto agree to amend the Employment Agreement as follows:

 

		1.	Amendments.

1.1        The
first sentence of Section 2.2. of the Employment Agreement is hereby deleted in its entirety and replaced with the following:

“During the Term
of Employment, the Executive shall be employed as the Company’s Chief Executive Officer, with such duties and responsibilities that
are consistent with such position as may be assigned by the Board (excluding the Executive) from time to time.”

1.2        The
first sentence of Section 2.3. of the Employment Agreement is hereby deleted in its entirety and replaced with the following:

“During the Term
of Employment, the Executive shall report to the Chief Executive Officer, and the Executive shall diligently and conscientiously devote
all of the Executive’s business time, attention, energy, skill and best efforts as necessary to the business and affairs of the
Company Group.

1.3        Section
3.1. of the Employment Agreement is hereby deleted in its entirety and replaced with the following:

“3.1.Base
Salary. During the Term of Employment, the Executive shall initially receive a base salary per annum of Four Hundred Fifty Thousand
Dollars ($450,000), payable in cash in accordance with the Company’s normal payroll practices as in effect from time to time. During
the Term of Employment, the Board may periodically review the Executive’s base salary and the Board (excluding the Executive) may,
in its sole discretion, set such base salary to an amount it determines to be appropriate, provided, however, that any reduction will
qualify as Good Reason under Section 1.11. The Executive’s base salary, as may be in effect from time to time, is referred to herein
as “Base Salary.”

1.4       The
first sentence of Section 3.2. of the Employment Agreement is hereby deleted in its entirety and replaced with the following:

“During
the Term of Employment, the Executive shall be eligible to earn an annual performance bonus based on the achievement of the performance
goals established by the Board or a committee thereof in its sole discretion, with an annual target bonus opportunity of forty percent
(40%) of the Base Salary and the potential to earn a higher bonus for above target performance, with the amount of any such bonus to be
determined in the sole discretion of the Board or a committee thereof, in any case, excluding the Executive (the “Annual Bonus”).”

    

     

    

1.5       Section
3.3. of the Employment Agreement is hereby deleted in its entirety and replaced with the following:

“3.3.Equity
Grants. Subject to the approval of the Company’s Board of Directors or its Compensation Committee, and the availability
of additional shares for grant under the Company’s 2017 Equity Incentive Plan, as amended (the “Plan”), you will be
granted restricted stock units for 1,000,000 shares of the Company’s common stock (the “RSU Award”), pursuant to the
terms of the Plan and the Restricted Stock Unit Agreement (collectively, the “RSU Agreement”). If granted, the RSU shall be
subject to vesting as follows: two-thirds of the shares subject to the RSU shall vest on and be issued on a pro rata basis over 24 months
and the balance shall vest and be issued on a pro rata basis over the following 12 months, provided that on the applicable vesting date
you are in the Company’s “Continuous Service” (as defined in the RSU Agreement). The RSU will be governed in full by
the terms of the Plan and your individual RSU Agreement. During the Term of Employment, the Executive shall be eligible for additional
equity or equity-based awards that may be granted to the Executive at such times, in such amounts and in such manner as the Board (excluding
the Executive) may determine in its sole discretion, but, in good faith, taking into account the roles of and responsibilities of Executive
relative to industry norms for similar positions. Any such equity or equity-based awards shall be subject to the terms and conditions
set forth in the applicable plan and award agreement.”

1.6       Sections
4.2.3. and 4.2.4. of the Employment Agreement are hereby deleted in their entirety and replaced with the following:

“4.2.3. Termination
Without Cause or for Good Reason–Not In Connection with a Change of Control. If, during the Term of Employment, the Executive’s
employment is terminated by the Company without Cause (and not due to death or Disability) or by Executive for Good Reason, in either
case, and such termination is not covered by Section 4.2.4, then the Executive shall be entitled to receive the Accrued Benefits and,
subject to Section 4.2.4: (i) the Unpaid Prior Year Bonus, with such amount to be payable in cash and/or fully vested shares of the Company’s
common stock (as determined by the Company in its sole discretion) at the same time as if no such termination had occurred; (ii) the Annual
Bonus for the year in which the Termination Date occurs, but multiplied by a fraction (A) the numerator of which is the number of days
in the fiscal year that have transpired through the Termination Date and (B) the denominator of which is the number of days in such fiscal
year (to be paid in cash and/or fully vested shares of the Company’s common stock (as determined by the Company in its sole discretion)
at the same time as if no such termination had occurred); (iii) continuation of the Base Salary as of the Termination Date for twelve
(12) months following the Termination Date, with all portions of such Base Salary to be paid in cash in equal installments in accordance
with the Company’s normal payroll policies, with the first such payment to be made on the sixtieth (60th) day following
the Termination Date and to include a catch-up covering any payroll dates between the Termination Date and the date of the first payment,
and (iv) the COBRA Benefit for a period of twelve (12) months following the Termination Date; provided, however, that notwithstanding
the foregoing, the COBRA Benefit shall not be provided to the extent that it would result in any fine, penalty or tax on the Company or
any of its Affiliates (under Section 105(h) of the Code or the Patient Protection and Affordable Care Act of 2010, or otherwise); provided
further, that the COBRA Benefit shall cease earlier if the Executive (or his dependents) become eligible for health coverage under the
health plan of another employer. All other rights the Executive may have to compensation and employee benefits from the Company or its
Affiliates, other than as set forth in this Section 4.2.3, shall immediately terminate upon the Termination Date.

    

     

    

 

4.2.4.       Termination
Without Cause or for Good Reason – In Connection with a Change of Control. If, during the Term of Employment, the Executive’s
employment is terminated by the Company without Cause (and not due to death or Disability) or by Executive for Good Reason, in either
case, (A) upon or within 24 months following a Change of Control or (B) within 60 days prior to such Change of Control, then the Executive
shall be entitled to receive the Accrued Benefits and, subject to Section 4.2.5: (i) the Unpaid Prior Year Bonus, with such amount to
be payable in cash and/or fully vested shares of the Company’s common stock (as determined by the Company in its sole discretion)
at the same time as if no such termination had occurred; (ii) a lump sum payment equal to two times the sum of Executive’s Base
Salary (at the highest rate in effect during the 24 month period commencing on the date of such Change of Control) and the higher of Executive’s
target Annual Bonus opportunity and the Annual Bonus paid to Executive with respect to the fiscal year immediately preceding the fiscal
year in which such termination occurred, with such payment to be paid in cash on the first payroll date after the effective date of the
release (as described in Section 4.2.5) and in all events no later than 70 days after such termination and (iii) a payment equal to 24
times the monthly COBRA premium for Executive and his eligible dependents (at the rate in effect for Executive’s coverage at the
time of his termination, regardless of whether Executive elects COBRA coverage), with two-thirds of such payment to be paid in cash on
the first payroll date after the effective date of the release (as described in Section 4.2.5) and in all events no later than 70 days
after such termination, and with the remaining one-third to be paid according to the same schedule as the COBRA Benefit is provided in
clause (iii) of Section 4.2.3 (i.e., in installments over 12 months following the Termination Date). Notwithstanding the foregoing, in
the event that a termination described in clause (B) of this Section 4.2.4 occurs, then the payments described in clauses (ii) and (iii)
of this Section 4.2.4 shall be paid over the same 12-month period and in the same manner as set forth in clauses (iii) and (iv) of Section
4.2.3, respectively, rather than being paid in a lump sum. In addition, if (and only if), during the Term of Employment, the Executive’s
employment is terminated by the Company without Cause (and not due to death or Disability) or by Executive for Good Reason, in either
case, upon or within 24 months following a Change of Control, then, to the extent the following will not result in a violation of Section
409A, the Executive shall be entitled to, in addition to the Accrued Benefits and the payments set forth in the foregoing clauses (i)
through (iii), and subject to Section 4.2.5, immediate and full accelerated vesting of all equity awards received by Executive from the
Company or any of its direct or indirect parent companies that are outstanding as of the Termination Date without regard for the vesting
schedule set forth in any applicable plan or agreement governing such equity awards; provided that, any equity awards that are subject
to the satisfaction of performance goals shall be deemed earned at not less than target performance; and provided, further, that, with
respect to any equity award that is in the form of a stock option or stock appreciation right, the option or stock appreciation right
shall remain outstanding and exercisable for 24 months following the Termination Date (but in no event beyond the expiration date of the
applicable option or stock appreciation right). All other rights the Executive may have to compensation and employee benefits from the
Company or its Affiliates, other than as set forth in this Section 4.2.4, shall immediately terminate upon the Termination Date.

4.2.5.       Release
Requirement. Payment and provision of the benefits set forth in Sections 4.2.2, 4.2.3, or 4.2.4 (other than the Accrued Benefits)
is subject to the Executive’s (or, as applicable, the Executive’s estate’s or legal representative’s) execution
of a general release of claims and covenant not to sue in form and substance satisfactory to the Company, such that such release becomes
effective, with all revocation periods having expired unexercised, within sixty (60) days after the Termination Date. Notwithstanding
the foregoing, if such sixty (60) day period ends in a calendar year after the calendar year in which the Executive’s employment
terminates, then to the extent required by Section 409A, any severance payment set forth in Sections 4.2.2, 4.2.3, or 4.2.4 (other than
the Accrued Benefits) that would have been made during the calendar year in which the Executive’s employment terminates instead
shall be withheld and paid on the first payroll date in the calendar year after the calendar year in which the Executive’s employment
terminates, with all remaining payments to be made as if no such delay had occurred.”

    

     

    

 

2.
Severability. The provisions of this Amendment are severable and if any part of it is found to be unenforceable the other
paragraphs shall remain fully valid and enforceable.

3.
No Other Amendments; Confirmation. All other terms of the Employment Agreement shall remain in full force and effect. The
Employment Agreement, as amended by this Amendment, constitutes the entire agreement between the parties with respect to the subject
matter thereof.

4.
Counterparts.  This Amendment may be executed in one or more counterparts, each of which shall be deemed an original
but both of which together shall constitute one and the same instrument.

5. Governing Law. This Amendment
is made and shall be construed and performed under the laws of the Commonwealth of Virginia without regard to its choice or conflict
of law principles and the parties agree to Virginia as the exclusive venue for any disputes arising hereunder. 

IN WITNESS WHEREOF, the parties hereto have
caused this Amendment to the Employment Agreement to be duly executed as of the day and year first above written.

 

	 	 	 
	 	 	 
	 	ADIAL PHARMACEUTICALS, INC.
	 	 	
     

     

	 	By: 	/s/ Joseph Truluck
	 	Name: 	Joseph Truluck
	 	Title: 	Chief Financial Officer
	 	 	 
	 	
     

     

    /s/ Cary J. Claiborne

	 	CARY J. CLAIBORNE

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00348-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00348-of-00352.parquet"}]]